The MedTech contract development and manufacturing organization (C(D)MO) market is entering a new phase. After years of pandemic-related demand disruption, inventory destocking, and geopolitical turbulence, the market is normalizing—and accelerating. MedTech OEMs are concentrating spend on fewer, more capable external partners. Platform consolidation is intensifying. And the M&A market, after a period of slower activity, is reopening with a growing pipeline of transactions. For C(D)MO leaders and investors seeking to understand where value lies — and how to capture it — the timing for a rigorous market assessment has rarely been more important.
Read the full article: MedTech C(D)MOs: Unlocking Growth and M&A Value //
Source: https://www.rolandberger.com/en/Insights/Publications/MedTech-C(D)MOs-Unlocking-growth-and-M-A-value.html